Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis.
Fibrosis is a harmful process that occurs in many diseases, when normal healthy tissue is replaced with scar tissue, compromising function and ultimately leading to organ failure.
Promedior's proprietary platform is based upon Pentraxin-2, a naturally-occurring human protein that is specifically active at the site of tissue damage and works as an agonist with the potential to both prevent and reverse fibrosis.
By acting as a master regulator upstream in the fibrosis cascade, pentraxin-2 therapeutics harness the innate healing power of the immune system and open up new opportunities to treat a wide range of systemic fibrotic diseases for which there are no approved therapies.
LEARN MORE >